Jim Hollingshead, CEO of Insulet and former connectivity wizard at ResMed, dives into the revolutionary impact of cloud technology on diabetes care. He discusses the Omnipod 5's integration with continuous glucose monitors, paving the way for more automated diabetes management. Hollingshead also highlights the differing needs of type 1 and type 2 diabetes patients and shares exciting growth opportunities in the insulin market. His insights into navigating challenges in healthcare bring a fresh perspective to patient care improvements.